What are Key Factors Hindering the Alpha-1 Antitrypsin Deficiency Market Growth?
Alpha-1 Antitrypsin Deficiency Overview
In the twenty-first century, public health has made a substantial contribution to the knowledge and management of diseases. An early diagnosis can still play a role in managing and treating serious illnesses. One of these rare genetic disorders, alpha-1 antitrypsin deficiency (AATD), has seen advancements in terms of awareness and factors considered during treatment.
Therapies for alpha-1 antitrypsin deficiency today mostly involves alpha-1 antitrypsin augmentation treatment. This is the procedure for extracting and injecting normal AAT from blood plasma. The current alpha-1 antitrypsin augmentation treatments include ARALAST (Takeda), GLASSIA (Kamada/Takeda), PROLASTIN/PROLASTIN-C (Grifols), ZEMAIRA (CSL Behring), and ALFALASTIN. The market for their therapy is worth billions of dollars, despite the fact that these drugs for alpha-1 antitrypsin insufficiency are pricey and do not have widespread approval. Grifols is the main rival in the US and some significant European countries.
The future of the AATD market looks promising
Despite the obstacles mentioned above and the delayed growth, the alpha-1 antitrypsin deficiency treatment market's changing environment appears promising, with the new medications having substantial potential despite their limitations. Arrowhead's fazirsiran is the leader of the group. The most advanced techniques use RNAi to specifically target AATD-related liver problems. Alpha-1 antitrypsin deficiency is currently managed using off-label therapies. Fazirsiran lessens the production of the Z-AAT protein, preventing severe AATD. This also explains why the Japanese corporation Takeda is interested in these goods to establish its foothold in the market for expensive alpha-1 antitrypsin deficiency treatments.
Despite the promising alpha-1 antitrypsin insufficiency pipeline, the aforementioned challenges must be taken into account. Two new patient-centered programmes have been developed in Europe to address these issues: the European Reference Network for Rare Lung Diseases (ERN-LUNG) and the European Alpha-1 Research Collaboration (EARCO). The two main objectives of ERN-LUNG are to establish quality control for AATD laboratories and a disease management programme. A pan-European registry for alpha-1 antitrypsin deficiency will be created by EARCO in order to manage and promote easy access to treatment options while also understanding natural history. Given these initiatives, it is anticipated that most problems with alpha-1 antitrypsin deficiency management and treatment will be solved soon.
Latest Links Related to the Alpha-1 Antitrypsin Deficiency Treatment Market;
https://factsnhealth.wordpress.com/2022/11/18/evaluating-the-major-growth-and-ongoing-developments-in-the-alpha-1-antitrypsin-deficiency-aatd-market/
https://themolecularhealth.blogspot.com/2022/11/key-companies-developing-therapies-in.html
https://hardyhealthcare.blogspot.com/2022/11/major-growth-factors-and-developments.html
.png)
Comments
Post a Comment